• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    TrovaGene, Inc. (TROV)

    4.02 Down 0.14(3.37%) Apr 29, 4:00PM EDT
    |After Hours : 3.90 Down 0.12 (2.99%) Apr 29, 5:50PM EDT
    ProfileGet Profile for:
    TrovaGene, Inc.
    11055 Flintkote Avenue
    Suite B
    San Diego, CA 92121
    United States - Map
    Phone: 858-952-7570
    Website: http://www.trovagene.com

    Index Membership:N/A
    Industry:Medical Laboratories & Research
    Full Time Employees:37

    Business Summary 

    Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, a cell-free molecular diagnostic platform that provides cancer monitoring by tracking and quantifying levels of cell-free DNA from either urine or blood samples, as well as intends to provide clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung cancer, as well as targeting clinically validated gene rearrangements, such as ALK, RET, and ROS. In addition, it offers laboratory developed tests for oncogene mutations to end users through a sales and marketing organization. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on TrovaGene, Inc.

    Corporate Governance 
    TrovaGene, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Mark Erlander Ph.D., 56
    Chief Scientific Officer
    Mr. William J. Welch M.B.A., 54
    Chief Exec. Officer
    Ms. Elizabeth Anderson ,
    VP of Fin. and Admin.
    Dr. Karsten Schmidt Ph.D., 54
    Sr. VP of Technology Operations
    Mr. David S. Moskowitz R.Ph.,MBA,
    VP of Investor Relations
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders